SPRO — Spero Therapeutics Share News
0.000.00%
Last trade - 00:00- $64.64m
- $13.87m
- $66.80m
Spero Therapeutics rises after upbeat results
Spero Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Spero Therapeutics Announces Fourth Quarter And Full Year 2022 Operating Results And Provides Business Update
Spero Therapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Spero Therapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Spero Therapeutics Inc Says Existing Cash And Cash Equivalents, Expected To Be Sufficient To Fund Operations And Capex Beyond 2024
Spero Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Spero Therapeutics Announces Third Quarter 2022 Operating Results
Spero Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Spero Therapeutics Closes Exclusive License Agreement With GSK For Tebipenem HBr
Spero Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Spero Therapeutics up after Evercore raises rating to 'outperform'
Press Digest: British Business - Sept 23
U.S. STOCKS ON THE MOVE-Stitch Fix, Faraday Future, Luminar Technologies, Tesla
U.S. STOCKS ON THE MOVE-Tesla, Eli Lilly, Darden Restaurants, UPS
U.S. STOCKS ON THE MOVE- Eli Lilly, Darden Restaurants, Spero Therapeutics
U.S. STOCKS ON THE MOVE- Spero Therapeutics, Salesforce, KB Home
Deals of the day-Mergers and acquisitions
Spero Therapeutics up after GSK eyes urinary tract infection drug candidate